Avalo Therapeutics AVTX Total Liabilities & Equity
Total Liabilities & Equity at other companies
Other financials
Where this comes from
Reported directly by Avalo Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.
The official record: Avalo Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Avalo Therapeutics's total liabilities & equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Avalo Therapeutics's total liabilities & equity?
- Avalo Therapeutics (AVTX) reported total liabilities & equity of $99.89M in Q1 2026.
- How has Avalo Therapeutics's total liabilities & equity changed year-over-year?
- Avalo Therapeutics's total liabilities & equity decreased by 27.9% year-over-year, from $138.52M to $99.89M.
- What is the long-term trend for Avalo Therapeutics's total liabilities & equity?
- Over 5 years (2020 to 2025), Avalo Therapeutics's total liabilities & equity has grown at a 21.6% compound annual growth rate (CAGR), from $43.76M to $116.46M.
- What does total liabilities & equity mean?
- Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.